相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The validity of progression-free survival 2 as a surrogate trial end point for overall survival
Rachel G. Woodford et al.
CANCER (2022)
Pembrolizumab (pembro) vs placebo as adjuvant therapy for patients (pts) with renal cell carcinoma (RCC): Patient-reported outcomes (PRO) in KEYNOTE-564
T. K. Choueiri et al.
ANNALS OF ONCOLOGY (2021)
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma
T. K. Choueiri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial
Tim Eisen et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
B. Escudier et al.
ANNALS OF ONCOLOGY (2019)
Sorafenib Versus Observation Following Radical Metastasectomy for Clear-cell Renal Cell Carcinoma: Results from the Phase 2 Randomized Open-label RESORT Study
Giuseppe Procopio et al.
EUROPEAN UROLOGY ONCOLOGY (2019)
Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis
Maxine Sun et al.
EUROPEAN UROLOGY (2018)
Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial
M. Gross-Goupil et al.
ANNALS OF ONCOLOGY (2018)
Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Systemic Therapy for Metastatic Renal-Cell Carcinoma
Toni K. Choueiri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Recurrence in Localized Renal Cell Carcinoma: a Systematic Review of Contemporary Data
Jacqueline M. Speed et al.
CURRENT UROLOGY REPORTS (2017)
Adjuvant Treatment for High-Risk Clear Cell Renal Cancer Updated Results of a High-Risk Subset of the ASSURE Randomized Trial
Naomi B. Haas et al.
JAMA ONCOLOGY (2017)
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial
Naomi B. Haas et al.
LANCET (2016)
Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy
A. Ravaud et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Multiple Testing in Group Sequential Trials Using Graphical Approaches
Willi Maurer et al.
STATISTICS IN BIOPHARMACEUTICAL RESEARCH (2013)
Patterns of recurrence and surveillance strategies for renal cell carcinoma following surgical resection
Alberto Breda et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2007)
Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system
JS Lam et al.
JOURNAL OF UROLOGY (2005)
Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma - A stratification tool for prospective clinical trials
BC Leibovich et al.
CANCER (2003)
分享论文
